This symposium was developed and funded by the medical department of Bristol Myers Squibb..
The bladder cancer landscape is rapidly evolving. At the European Association of Urology (EAU) 2024 Congress, Jürgen Gschwend, Department of Urology, Hôpital Rechts der Isar, Technical University of Munich, Germany, and Matthew Galsky, Medical Oncologist, The Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, New York, USA, review the current treatment landscape of muscle-invasive bladder cancer (MIBC) and discuss the impact of recent data on contemporary management of muscle-invasive urothelial carcinoma (MIUC). They also explore the evolution of the patient journey and challenges for a multi-disciplinary approach to treating MIUC.
Speakers
Jürgen Gschwend
Hôpital Rechts der Isar, Technical University of Munich, Germany
Matthew Galsky
The Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, New York, USA
Chapters:
Start – 1:21: Welcome and Introduction – Jürgen Gschwend
1:22 – 16:13: MIUC treatment landscape – Jürgen Gschwend
16:14 – 38:00: What we have learned from MIUC trials to date – Matthew Galsky
38:01 – End: Case studies – All
ONC-FR-2400203-NP-May-2024
